Paradigm Biocapital Advisors LP Purchases 1,509,547 Shares of Immatics (NASDAQ:IMTX)

Paradigm Biocapital Advisors LP lifted its position in shares of Immatics (NASDAQ:IMTX - Free Report) by 38.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,414,409 shares of the company's stock after buying an additional 1,509,547 shares during the period. Immatics comprises about 1.3% of Paradigm Biocapital Advisors LP's investment portfolio, making the stock its 18th largest holding. Paradigm Biocapital Advisors LP owned 4.54% of Immatics worth $38,496,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of the company. T. Rowe Price Investment Management Inc. boosted its position in shares of Immatics by 43.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 10,604,777 shares of the company's stock worth $75,400,000 after buying an additional 3,225,141 shares during the period. Wellington Management Group LLP boosted its position in Immatics by 7.6% during the fourth quarter. Wellington Management Group LLP now owns 10,417,892 shares of the company's stock valued at $74,071,000 after purchasing an additional 736,709 shares during the last quarter. Baker BROS. Advisors LP boosted its position in Immatics by 12.9% during the fourth quarter. Baker BROS. Advisors LP now owns 7,275,830 shares of the company's stock valued at $51,731,000 after purchasing an additional 832,432 shares during the last quarter. Braidwell LP boosted its position in Immatics by 112.7% during the fourth quarter. Braidwell LP now owns 3,503,965 shares of the company's stock valued at $24,913,000 after purchasing an additional 1,856,400 shares during the last quarter. Finally, Orbimed Advisors LLC boosted its position in Immatics by 53.9% during the fourth quarter. Orbimed Advisors LLC now owns 3,087,462 shares of the company's stock valued at $21,952,000 after purchasing an additional 1,081,081 shares during the last quarter. 64.41% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald reissued an "overweight" rating on shares of Immatics in a research report on Tuesday, April 1st.

Immatics Trading Up 1.1%

NASDAQ:IMTX traded up $0.05 on Friday, hitting $4.74. The company's stock had a trading volume of 605,309 shares, compared to its average volume of 654,261. The stock has a fifty day moving average of $4.48 and a two-hundred day moving average of $5.87. The firm has a market capitalization of $576.15 million, a P/E ratio of -7.18 and a beta of 0.87. Immatics has a one year low of $3.30 and a one year high of $13.77.

Immatics (NASDAQ:IMTX - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.04. The firm had revenue of $20.12 million for the quarter, compared to analyst estimates of $14.92 million. Immatics had a negative return on equity of 15.90% and a negative net margin of 47.94%. As a group, sell-side analysts anticipate that Immatics will post -0.72 EPS for the current year.

Immatics Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.